Audrey Thomas-Schoemann

Audrey Thomas-Schoemann

Auto-generated profile, based on publicly available information

Audrey Thomas-Schoemann

Assistance publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MMManuela Tiako Meyo
Manuela Tiako Meyo
AJAnne Jouinot
Anne Jouinot
ELEtienne Giroux Leprieur
Etienne Giroux Leprieur
Elizabeth FabreElizabeth Fabre
Elizabeth Fabre
MWMarie Wislez
Marie Wislez
Benoit BlanchetBenoit Blanchet
Benoit Blanchet
A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial Growth Factor A (VEGFA), soluble CD40 ligand (sCD40L) and soluble CD44 (sCD44), with survival in nivolumab-treated metastatic non-small cell lung cancer (NSCLC) patients. Plasma biomarkers were assayed at baseline and after two cycles of nivolumab. A cut-off of positivity for sPD-1, sPD-L1 and sCD40L expressions was defined as a plasma level above the lower limit of quantification. Baseline sPD-1 and sPD-L1 levels were subsequently analyzed in a control group of EGFR-mutated (Epidermal Growth Factor Receptor) NSCLC patients. Association between survival and biomarkers was investigated using Cox proportional hazard regression model. Eighty-seven patients were included (51 nivolumab-treated patients, 36 in EGFR-mutated group). In nivolumab group, baseline sPD-1, sPD-L1 and sCD40L were positive for 15(29.4%), 27(52.9%) and 18(50%) patients, respectively. We defined a composite criteria (sCombo) corresponding to sPD-1 and/or sPD-L1 positivity for each patient. In nivolumab group, baseline sCombo positivity was associated with shorter median progression-free survival (PFS) (78 days 95%CI (55–109) vs. 658 days (222-not reached); HR: 4.12 (1.95–8.71), p = 0.0002) and OS (HR: 3.99(1.63–9.80), p = 0.003). In multivariate analysis, baseline sCombo independently correlated with PFS (HR: 2.66 (1.17–6.08), p = 0.02) but not OS. In EGFR-mutated group, all patients were baseline sCombo positive; therefore this factor was not associated with survival. After two cycles of nivolumab, an increased or stable sPD-1 level independently correlated with longer PFS (HR: 0.49, 95%CI (0.30–0.80), p = 0.004) and OS (HR: 0.39, 95%CI (0.21–0.71), p = 0.002). VEGFA, sCD40L and sCD44 did not correlate with survival. We propose a composite biomarker using sPD-1and sPDL-1 to predict nivolumab efficacy in NSCLC patients. A larger validation study is warranted.

1 January 2014 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ATAudrey Thomas-Schoemann
Audrey Thomas-Schoemann
BBBenoit Blanchet
Benoit Blanchet
CBChristophe Bardin
Christophe Bardin
GNGaëlle Noé
Gaëlle Noé
PBPascaline Boudou-Rouquette
Pascaline Boudou-Rouquette
FGFrançois Goldwasser
François Goldwasser

1 December 2012 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ATAudrey Thomas-Schoemann
Audrey Thomas-Schoemann
FBFrederic Batteux
Frederic Batteux
CMCéline Mongaret
Céline Mongaret
Carole NiccoCarole Nicco
Carole Nicco
CCChristiane Chéreau
Christiane Chéreau
JAJérôme Alexandre
Jérôme Alexandre
In the presence of normal serum, complement component C3 is deposited on pneumococci primarily via the classical pathway. Pneumococcal surface protein A (PspA), a major virulence factor of pneumococci, effectively inhibits C3 deposition. PspA’s C terminus has a choline-binding domain that anchors PspA to the phosphocholine (PC) moieties on the pneumococcal surface. C-reactive protein (CRP), another important host defense molecule, also binds to PC, and CRP binding to pneumococci enhances complement C3 deposition through the classical pathway. Using flow cytometry of PspA+ and PspA− strains, we observed that the absence of PspA led to exposure of PC, enhanced the surface binding of CRP, and increased the deposition of C3. Moreover, when the PspA− mutant was incubated with a pneumococcal eluate containing native PspA, there was decreased deposition of CRP and C3 on the pneumococcal surface compared with incubation with an eluate from a PspA− strain. This inhibition was not observed when a recombinant PspA fragment, which lacks the choline-binding region of PspA, was added to the PspA− mutant. Also, there was much greater C3 deposition onto the PspA− pneumococcus when exposed to normal mouse serum from wild-type mice as compared with that from CRP knockout mice. Furthermore, when CRP knockout mouse serum was replenished with CRP, there was a dose-dependent increase in C3 deposition. The combined data reveal a novel mechanism of complement inhibition by a bacterial protein: inhibition of CRP surface binding and, thus, diminution of CRP-mediated complement deposition.

1 August 2020 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
FSFlorian Slimano
Florian Slimano
ABAmandine Baudouin
Amandine Baudouin
JZJérémie Zerbit
Jérémie Zerbit
ATAnne Toulemonde-Deldicque
Anne Toulemonde-Deldicque
ATAudrey Thomas-Schoemann
Audrey Thomas-Schoemann
CRCatherine Rioufol
Catherine Rioufol

13 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ABAudrey Bellesoeur
Audrey Bellesoeur
EOEdouard Ollier
Edouard Ollier
MAMarie Allard
Marie Allard
LHLaure Hirsch
Laure Hirsch
PBPascaline Boudou-Rouquette
Pascaline Boudou-Rouquette
Benoit BlanchetBenoit Blanchet
Benoit Blanchet
Pharmacokinetic/pharmacodynamic data from real-world cohort are sparse in non small–cell lung cancer (NSCLC) patients treated with nivolumab. The aim of this prospective observational study was to explore the exposure-response relationship for effectiveness and toxicity of nivolumab in 81 outpatients with metastatic lung cancer. Nivolumab plasma trough concentrations (Cmin) were assayed at days 14, 28, and 42. Prognostic factors (including Cmin) regarding progression-free survival (PFS) and overall survival (OS) were explored using a multivariate Cox model. A Spearman’s rank test was used to investigate the relationship between Cmin and grade >2 immune-related adverse events (irAE). Mean nivolumab Cmin was 16.2 ± 6.0 µg/mL (n = 76), 25.6 ± 10.2 µg/mL (n = 64) and 33.4 ± 11.3 µg/mL (n = 53) at days 14, 28, and 42, respectively. No pharmacokinetic/pharmacodynamic (PK/PD) relationship was observed with either survival or onset of irAE. Multivariable Cox regression analysis identified Eastern Cooperative Oncology Group Performance Status (hazard ratio 1.85, 95%confidence interval 1.02–3.38, p-value = 0.043) and baseline use of corticosteroids (HR 8.08, 95%CI 1.78–36.62, p-value = 0.007) as independent risk factor for PFS and only baseline use of corticosteroids (HR 6.29, 95%CI 1.46–27.08, p-value = 0.013) for OS. No PK/PD relationship for nivolumab was observed in real-world NSCLC patients. This supports the recent use of flat dose regimens without plasma drug monitoring.

19 May 2017 in Targeted Oncology
Verified
Journal Article
Closed access
PDF file
FGFanny Garlan
Fanny Garlan
BBBenoit Blanchet
Benoit Blanchet
NKNora Kramkimel
Nora Kramkimel
APAlicja Puszkiel
Alicja Puszkiel
JGJean-Louis Golmard
Jean-Louis Golmard
ATAudrey Thomas-Schoemann
Audrey Thomas-Schoemann